ISDA: 5C9C

Deposition Date 2015-06-26

Release Date 2015-07-15

Last Version Date 2023-09-27

Entry Detail

PDB ID:

5C9C

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Trichoplusia ni

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.70 Å

R-Value Free:

0.23

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein kinase B-raf
Gene (Uniprot):BRAF
Mutagens:V600E
Chain IDs:A, B
Chain Length:307
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P15056 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

4Z5

Primary Citation

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Peng, S.B, Henry, J.R, Kaufman, M.D, Lu, W.P, Smith, B.D, Vogeti, S, Rutkoski, T.J, Wise, S, Chun, L, Zhang, Y, Van Horn, R.D, Yin, T, Zhang, X, Yadav, V, Chen, S.H, Gong, X, Ma, X, Webster, Y, Buchanan, S, Mochalkin, I, Huber, L, Kays, L, Donoho, G.P, Walgren, J, McCann, D, Patel, P, Conti, I, Plowman, G.D, Starling, J.J, Flynn, D.L, Henry, J.R, Kaufman, M.D, Peng, S.B, Ahn, Y.M, Caldwell, T.M, Vogeti, L, Telikepalli, H, Lu, W.P, Hood, M.M, Rutkoski, T.J, Smith, B.D, Vogeti, S, Miller, D, Wise, S.C, Chun, L, Zhang, X, Zhang, Y, Kays, L, Hipskind, P.A, Wrobleski, A.D, Lobb, K.L, Clay, J.M, Cohen, J.D, Walgren, J.L, McCann, D, Patel, P, Clawson, D.K, Guo, S, Manglicmot, D, Groshong, C, Logan, C, Starling, J.J, Flynn, D.L.Show

Cancer Cell 28 384 398 (2015)

PMID: 26343583 DOI: 10.1016/j.ccell.2015.08.002

Abstact

LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers. Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities. LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers. Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers. Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form